Compare SLQT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLQT | ALLO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.9M | 252.9M |
| IPO Year | 2020 | 2018 |
| Metric | SLQT | ALLO |
|---|---|---|
| Price | $0.98 | $1.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $3.88 | ★ $8.27 |
| AVG Volume (30 Days) | 1.3M | ★ 7.1M |
| Earning Date | 02-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,563,142,000.00 | N/A |
| Revenue This Year | $13.00 | N/A |
| Revenue Next Year | $7.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.16 | N/A |
| 52 Week Low | $1.33 | $0.86 |
| 52 Week High | $6.86 | $3.78 |
| Indicator | SLQT | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 28.11 | 51.61 |
| Support Level | $1.38 | $1.46 |
| Resistance Level | $1.49 | $1.97 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 2.76 | 36.89 |
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.